CELG Celgene Corporation

   By Stephen Nakrosis 
 

Celgene Corporation (CELG) on Tuesday said results from an open-label phase II/III National Clinical Trials Network study showed single-agent Revlimid achieved a statistically significant improvement in the primary endpoint of progression-free survival compared to observation.

The study was led by the ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute, part of the National Institutes of Health. Revlimid was provided under a clinical trials agreement with the NCI's Division of Cancer Treatment and Diagnosis.

Based on the preliminary results of the study, safety was consistent with the known safety profile of Revlimid.

"In multiple myeloma, there has been an important question regarding the risks and benefits of treating patients with smoldering myeloma. We believe that the properties of Revlimid could play an important role in delaying the progression of smoldering myeloma into active myeloma," said Jay Backstrom, chief medical officer for Celgene.

The company also said Tuesday that Dr. Alise Reicin had been named President, Global Clinical Development, effective November 1, 2018. In this role, Dr. Reicin will be responsible for all aspects of mid- to late-stage clinical development across Celgene's portfolio and will serve on the company's Executive Committee.

Dr. Reicin was most recently Senior Vice President and Head of Global Clinical Development in Research and Development at EMD Serono, the biopharmaceutical business of Merck KGaA, in Darmstadt, Germany.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

October 23, 2018 17:46 ET (21:46 GMT)

Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024

Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024